XML 50 R37.htm IDEA: XBRL DOCUMENT
v3.26.1

Related Party - Gilead Sciences, Inc. (Details) shares in Millions, $ in Millions | 3 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | ---
Mar. 31, 2026 USD ($) program member | Mar. 31, 2025 USD ($) shares | Dec. 31, 2023 USD ($) program | Dec. 31, 2021 USD ($) program | Dec. 31, 2020 USD ($) | Dec. 31, 2025 USD ($) | Dec. 31, 2024 USD ($)
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Sale of stock, consideration received on transaction |  | $ 150.0 |  |  |  |  |
Number of programs, eligible to receive regulatory and commercial milestone payments | program |  |  | 4 |  |  |  |
Revenue recognized from amounts in deferred revenue at the beginning of the period | $ 17.0 | 28.0 |  |  |  |  |
Accounts payable, current | $ 39.0 |  |  |  |  | $ 42.0 |
Gilead |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Sale of stock, consideration received on transaction |  | $ 15.0 |  |  |  |  |
Gilead |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Sale of stock, number of shares acquired in transaction (in shares) | shares |  | 1.4 |  |  |  |  |
Related Party |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Percentage of outstanding common stock held | 25.00% |  |  |  |  |  |
Accounts payable, current | $ 11.0 |  |  |  |  | $ 24.0 |
Related Party | Research and Development |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Reimbursement from related party for shared costs |  | $ (5.0) |  |  |  |  |
Purchase Agreement | Related Party |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Number of board members | member | 3 |  |  |  |  |  |
Gilead Collaboration Agreement |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Option payment upon completion of certain IND-enabling activities | $ 60.0 |  |  |  |  |  |
Option payment upon achievement of certain development milestones | $ 150.0 |  |  |  |  |  |
Gilead Collaboration Agreement | Related Party |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Collaboration term for current and future clinical programs |  |  |  |  | 10 years |  |
Option continuation payment due upon second anniversary of agreement |  |  |  |  | $ 100.0 |  |
Option continuation payment due upon fourth anniversary of agreement |  |  |  |  | 100.0 |  | $ 100.0
Option continuation payment due upon sixth anniversary of agreement |  |  |  |  | 100.0 |  |
Option continuation payment due upon eighth anniversary of agreement |  |  |  |  | 100.0 |  |
Upfront cash payment |  |  |  |  | $ 175.0 |  |
Option fee per program for all other programs entering clinical development to exercise option |  |  |  | $ 150.0 |  |  |
Number of research programs | program | 2 |  |  |  |  |  |
Revenue recognized from amounts in deferred revenue at the beginning of the period | $ 15.0 | $ 28.0 |  |  |  |  |
Gilead Collaboration Agreement | Related Party | Maximum |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Potential regulatory approval milestones payment receivable related to domvanalimab |  |  |  | $ 500.0 |  |  |
Amended Gilead Collaboration Agreement |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Number of exercise option to programs | program |  |  |  | 3 |  |  |
Option payments received |  |  |  | $ 725.0 |  |  |
Removal of option continuation payment under agreement |  |  |  | $ 100.0 |  |  |
Option payment upon achievement of certain development milestones |  |  | $ 150.0 |  |  |  |
Number of programs, eligible to receive regulatory and commercial milestone payments | program |  |  | 2 |  |  |  |
Amended Gilead Collaboration Agreement | Related Party |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Upfront cash payment |  |  | $ 17.5 |  |  |  |
Number of research programs | program |  |  | 2 |  |  |  |
Option payment upon completion of certain IND-enabling activities |  |  | $ 45.0 |  |  |  |
Total upfront cash payment |  |  | 35.0 |  |  |  |
Amended Gilead Collaboration Agreement | Related Party | Maximum |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |
Regulatory and commercial milestone payments received |  |  | $ 375.0 |  |  |  |

X
- Definition Collaboration term for current and future clinical programs. + References No definition available. + Details
Name: | rcus_CollaborationTermForCurrentAndFutureClinicalPrograms
Namespace Prefix: | rcus_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Board Members + References No definition available. + Details
Name: | rcus_NumberOfBoardMembers
Namespace Prefix: | rcus_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of exercise option to programs. + References No definition available. + Details
Name: | rcus_NumberOfExerciseOptionToPrograms
Namespace Prefix: | rcus_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of programs, eligible to receive regulatory and commercial milestone payments. + References No definition available. + Details
Name: | rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments
Namespace Prefix: | rcus_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of research programs. + References No definition available. + Details
Name: | rcus_NumberOfResearchPrograms
Namespace Prefix: | rcus_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Option continuation payment due upon Eighth anniversary of agreement. + References No definition available. + Details
Name: | rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Option continuation payment due upon Fourth anniversary of agreement. + References No definition available. + Details
Name: | rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Option continuation payment due upon second anniversary of agreement. + References No definition available. + Details
Name: | rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Option continuation payment due upon Sixth anniversary of agreement. + References No definition available. + Details
Name: | rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Option fee per program for all other programs entering clinical development to exercise option. + References No definition available. + Details
Name: | rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Option payment received. + References No definition available. + Details
Name: | rcus_OptionPaymentReceived
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Option payment upon achievement of certain development milestones. + References No definition available. + Details
Name: | rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Option payment upon completion of certain IND-enabling activities. + References No definition available. + Details
Name: | rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of outstanding common stock owned. + References No definition available. + Details
Name: | rcus_PercentageOfOutstandingCommonStockOwned
Namespace Prefix: | rcus_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Potential regulatory approval milestones payment receivable related to domvanalimab. + References No definition available. + Details
Name: | rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Regulatory and commercial milestone payments received. + References No definition available. + Details
Name: | rcus_RegulatoryAndCommercialMilestonePaymentsReceived
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Related party transaction reimbursement from related party for shared costs. + References No definition available. + Details
Name: | rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Remove option continuation payment under agreement. + References No definition available. + Details
Name: | rcus_RemoveOptionContinuationPaymentUnderAgreement
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sale Of Stock, Number Of Shares Acquired In Transaction + References No definition available. + Details
Name: | rcus_SaleOfStockNumberOfSharesAcquiredInTransaction
Namespace Prefix: | rcus_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total Upfront Cash Payment + References No definition available. + Details
Name: | rcus_TotalUpfrontCashPayment
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront cash payment. + References No definition available. + Details
Name: | rcus_UpfrontCashPayment
Namespace Prefix: | rcus_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details
Name: | us-gaap_AccountsPayableCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(k)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(k)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cash received on stock transaction after deduction of issuance costs. + References No definition available. + Details
Name: | us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=rcus_GileadSciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=rcus_CommonStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=rcus_OptionLicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=rcus_AmendedGileadCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |